… ProQR Announces Proposed Public Offering of Ordinary Shares … LEIDEN, the Netherlands, Nov. 13, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical … public offering. All of the shares are being offered by ProQR. In addition, in the public offering, ProQR expects to …
… ProQR Appoints Theresa Heggie as Chief Commercial Officer … (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through the … brings a wealth of commercial and leadership skills to ProQR, having built commercial organizations and successfully …
LEIDEN, Netherlands & CAMBRIDGE, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that it will
… ProQR to Present at Upcoming SVB Leerink Conference LEIDEN, … will be accessible from the “Investors & Media” section of ProQR’s website ( www.proqr.com ) under “ Events ”. Archived webcasts will be …
… ProQR to Present at Cowen Health Care Conference LEIDEN, … be accessible from the ‘Investor Relations’ section of ProQR’s website ( www.proqr.com ) under ‘Events and Presentations’. The …
… ProQR Announces Presentations at the OTS Annual Meeting … the Netherlands, Sept. 24, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … clinical data in LCA10 David Rodman, MD, EVP of R&D of ProQR, will give a presentation on the recent clinical data …
Preclinical proof of concept data for the AX-0810 program targeting NTCP for cholestatic diseases presented at ASGCT 27th Annual Meeting – Management to host webinar today at 8:00 am EDT to highlight dataMartin Maier, PhD nominated to Board with Annual General
Preclinical and translational pipeline program data for AX-0810 for Cholestatic Diseases targeting NTCP and AX-1412 for Cardiovascular Disease targeting B4GALT1 anticipated in 2024, building further momentum toward the clinicAccelerated development of Axiomer™ for CNS ap
Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Strengthened leadership with appointments of Chief Financial Officer and Chief
AX-0810 target engagement data in healthy volunteers on track for Q2 2026; biliary atresia selected as initial Phase 2 indicationPipeline expansion with advancement of AX-0811 (NTCP) and AX-0422 (IDUA) toward the clinic, supporting multiple upcoming clinical cataly